Shares in Active Biotech AB climbed more than 12 percent Monday on news that the company earned a €10 million milestone payment from its partner, Ipsen SA, after reaching the halfway point in recruitment onto a 1,200-patient, Phase III registration trial of tasquinimod in metastatic castrate-resistant prostate cancer.